Its radiolabeled form, 68Ga-FAP-2286, demonstrated sustained tumor uptake in a Phase I trial, supporting its role in baseline imaging and therapy monitoring across several solid tumors (e.g., breast, colorectal, sarcoma) [146]. Here, FAP is linked to neoplasm.